Hemostemix (CVE:HEM) Shares Up 29.4% – Time to Buy?

Hemostemix Inc. (CVE:HEM) shares shot up 29.4% on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. 602,760 shares traded hands during trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.

Hemostemix Price Performance

The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The firm has a market capitalization of C$20.73 million, a P/E ratio of -4.07 and a beta of 1.25. The business has a fifty day moving average of C$0.09 and a 200-day moving average of C$0.10.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.